Attenuating Atherosclerosis through Inhibition of the NF-κB/NLRP3/IL-1β Pathway-Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)

Figure 2

VSMCs (CRL-1999) were treated with Res (10 μM) for indicated time. (a–d) The mRNA levels of NLRP3 and caspase-1, GSDMD, and IL-1β were determined by qPCR. Data are expressed as . vs. control group; , vs. AS group. (e, f) The protein levels of NLRP3 and pro-caspase-1, caspase-1, GSDMD, and pro-IL-1β, IL-1β, and IL-18 were determined by western blotting. (g–m) Quantification of the results shown in (e, f). Data are expressed as . , vs. control group; , vs. AS group. (n–q) Representative immunofluorescent staining images for NLRP3 and caspase-1, GSDMD, and IL-1β (green) (magnification: ×400, scale bar = 20 μm).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)

(q)